Impact of the $^{68}\text{Ga}$ Prostate-Specific Membrane Antigen ($^{68}\text{Ga}$-PSMA) PET/CT on the Management of Prostate Cancer

Surampalli Gurunath*, Shreeya Salunke and Sravan Komittishetty

Department of Pharmacology and Toxicology, Bharat Institute of Technology, Mangalpally, Ibrahimpatnam, Hyderabad, Telangana State, India

Abstract

This review discusses the efficiency and sensitivity of $^{68}\text{Ga}$-labelled prostate-specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT) imaging in comparison to other radiotracers and imaging techniques. It also conveys its impact on the treatment or management of prostate cancer patients. PSMA, observed in almost all prostate cancer cells, is used for staging and treatment, due to its high multiplicity in this cancer when compared to normal tissues. PSMA PET/magnetic resonance imaging (MRI) has applications in the management of prostate cancer. Though PSMA PET/MRI has yielded preliminary results, it is still studied as an imaging biomarker for tumor responses. PSMA-PET/CT is known for its highly sensitive resolution, as it lights up only the parts harboring prostate cancer or tumor cells and not any other kind of lesion. Therefore, $^{68}\text{Ga}$-PSMA-PET imaging is chosen over other variants of $^{68}\text{Ga}$-PSMA-11, such as $^{177}\text{Lu}$-PSMA or $^{225}\text{Ac}$-PSMA, and it is used for its greater ability to detect metastatic sites in patients with biochemical recurrence and low serum prostate-specific antigens values. The efficacy of $^{68}\text{Ga}$-PSMA-PET/CT also allows for estimation of oligometastases, as it supports the design of therapeutic trials in measuring long-term effects in patients. Finally, $^{68}\text{Ga}$-PSMA PET/CT is effective in identifying recurrence localization and, hence, permits the ability to choose the best therapeutic strategy as early as possible.

Introduction

Prostate cancer (PCa) holds the second position for most commonly occurring cancer and is a remarkable cause for the majority of death in men. According to research conducted in the UK, the incidence of PCa has increased by 44% since 1990. Every year in Australia and the UK, death of men due to PCa (3,306 deaths in Australia; 12,032 deaths in the UK) is more than the death of women due to breast cancer (3,058 deaths in Australia; 11,371 deaths in the UK). Twenty-sixty percent of patients treated for PCa fail primary therapy, and less than thirty percent of the patients having high-volume metastatic disease achieve 5-year survival.

Imaging techniques like computed tomography (CT) or magnetic resonance imaging (MRI) are used for staging of cancer. In non-metastatic cancer patients, about 30–35% patients treated by radical prostatectomy (RP) or radiotherapy (RT) have a rise in the prostate-specific antigens (PSA) levels and biochemical recurrence (BCR) in the years following treatment. Increasing levels of PSA after RT or surgery indicate a higher risk of death in men. These high levels of PSA and the early PSA failure in patients indicates a greater need for $^{68}\text{Ga}$-prostate-specific membrane antigen (PSMA) positron emission tomography (PET)/CT scanning. Treatment or management strategies differ for each patient depending on their risk, which usually increases after therapies like hormonal therapy, RT, chemotherapy or sometimes a combination of all these therapies.

PSMA is a glycoprotein present on the outer surface of prostate cells, hyper-regulated during metastatic conditions and castrate-resistant PCa (CRPC). Though the exact functions of PSMA are yet to be defined, it is still used for staging and treatment due to its high multiplicity in PCa. Many other malignancies, namely breast cancer, colorectal carcinoma, follicular lymphoma, etc., also express PSMA with $^{68}\text{Ga}$-PSMA avidness. Highly expressed PSMA (type-II-transmembrane glycoprotein) is also observed in almost all PCa cells, except the 5–10% of PCa cells without PSMA expression. In 2016, a study in Brazil estimated 61,200 new cases of PCa, which made it the second most prevailing neoplasia in men throughout the country and the third most common reason of death by cancer in men of Western countries.

Keywords: Oligometastases; Metastatic sites; Nodal metastasis; Baseline staging.

Abbreviations: BCR, biochemical recurrence; CRPC, castration-resistant prostate cancer; CT, computed tomography; FCH, fluciclovine; FDG, fluorodeoxyglucose; MRI, magnetic resonance imaging; mp-MRI, multi-parametric magnetic resonance imaging; PCa, prostate cancer; PET, positron emission tomography; PSA, prostate-specific antigens; PSMA, prostate-specific membrane antigen; RLT, radioligand therapy; RP, radical prostatectomy; RT, radiotherapy.

Received: April 25, 2020; Revised: May 13, 2020; Accepted: May 22, 2020

*Correspondence to: Surampalli Gurunath, Department of Pharmacology and Toxicology, Bharat Institute of Technology, Mangalpally, Ibrahimpatnam, Hyderabad, Telangana State, India. Tel: (+91)-9966555909; E-mail: s.gurunath1979@gmail.com

How to cite this article: Gurunath S, Salunke S, Komittishetty S. Impact of the $^{68}\text{Ga}$ Prostate-Specific Membrane Antigen ($^{68}\text{Ga}$-PSMA) PET/CT on the Management of Prostate Cancer. J Explor Res Pharmacol 2020;5(3):42–46. doi: 10.14218/JERP.2020.00009.
efficiency and sensitivity of $^{68}$Ga-PSMA PET/CT imaging in comparison to other radiotracers and imaging techniques. It also conveys its impact on the treatment or management of PCa patients.

**PSMA-PET and PSMA-PET/CT Technique**

PSMA-PET increases its positivity with an increase in the grade and stage of the tumor, level of PSA, and time. PSMA expression is linked directly to the status of disease (PCa) and therapeutic effects, indicating a parallel relationship with PSA values in treatment techniques like RT, chemotherapy and radionuclide therapies (with $^{177}$Lu,$^{225}$Ac-PSMA or $^{223}$Ra). PSMA-PET has a specific molecular imaging target for tumors expressing PSMA. Each imaging modality has a specific capability of identifying the sites of the tumor that would otherwise be neglected or considered negative by the other techniques. Hence, PSMA-PET is emerging as the most favorable imaging tool and a potential prognostic biomarker. PET scanning by using various tracers poorly detects early BCR with low levels of PSA. Only $^{68}$Ga-PSMA-PET imaging is used due to its precise detection of metastatic sites in patients having BCR with low serum PSA values.

PSMA-PET/CT has a highly sensitive resolution to detect tumors as small as 3 mm, across the lymph nodes. It is highly specific, as it lights up only the parts having PCa or any tumor tissue and not any kind of lesion which may look like PCa. Also, PSMA-based imaging shows improved detection in those patients having primary PCa (intermediate to high risk) when compared to CT or multi-parametric (mp-)MRI, making bone scintigraphy or additional cross-sectional imaging unnecessary.

**$^{68}$Ga-PSMA PET/CT-11**

$^{68}$Ga-PSMA PET/CT-11 is a PSMA tracer, wherein Ga-68 is a radioactive carrier and PSMA-11 is a small molecule that binds to the receptor. An automated synthesis system usually synthesizes Ga-68 of high efficiency and purity. PSMA radiotracers are given in micrograms so that no side-effects or adverse effects are perceived. These tracers are now widely used in PET and CT, due to their higher efficacy and precision in PCa scans when compared to bone scanning or MRI. PSMA radiotracers, given to hundreds of thousands of patients globally, have no reported side effects. Presently, using $^{68}$Ga, the physiological biodistribution of radiolabeled PSMA includes various glands, like salivary and lacrimal, other organs, like liver and spleen, and low-level uptake in the prostate tissue. The specificity and sensitivity of $^{68}$Ga-PSMA PET/CT estimates the detection of PCa as it supports the design of therapeutic trials in measuring long-term effects in patients. Hence, $^{68}$Ga-PSMA PET/CT is a novel imaging technique that detects BCR with greater sensitivity and is effective in identifying recurrence localization and permitting the choice for the best therapeutic strategy as early as possible.

**Variants of $^{68}$Ga-PSMA-11**

$^{177}$Lu-PSMA, a variant of $^{68}$Ga-PSMA-11, is also used for PET/CT imaging. Lutetium-177 is a short-path length beta emitter, having a crossfire effect of targeting all cells in 1 mm radius by supplying effective radiation only to the tumor, reducing the damage to other normal cells/tissues around it. The single-center, single-arm phase-2 trial, is the only trial showing that $^{177}$Lu-PSMA radioligand therapy (RLT) has a favorable anti-tumor activity and toxicity profile, depicting a significant improvement in the mCRPC patients with disease progression though treated with standard options/procedures.

**Impact of the $^{68}$Ga-PSMA PET/CT on Management Changes**

$^{68}$Ga-PSMA PET/CT has been reported to be of greater clinical importance to stage primary PCa. Roach et al. reported that management changes after PCa detection using $^{68}$Ga-PSMA PET/CT accounted for one-fifth of all the patients imaged. The management changes were suggested as a change from hormonal and

DOI: 10.14218/JERP.2020.00009 | Volume 5 Issue 3, September 2020
radical therapy to surgery (namely prostatectomy, regional lymph node detection), radiation treatment, systemic therapy, additional biopsies, and imaging. Replanning the treatment due to the prognostic implication in these patients is substantia. Bluemel et al.38 showed management changes in about 40% of the patients due to ⁶⁸Ga-PSMA PET/CT. Salvage RT in the presence of BCR or PSA was suggested as a management change after prior radical therapy.

Müller et al.49 reported that the overall management changes of ⁶⁸Ga-PSMA PET/CT were 60% (122/203). The use of metastasis-targeted treatment increased with a decrease in systemic treatment due to management changes, like targeted RT with and without hormonal therapy, based on the ⁶⁸Ga-PSMA PET/CT scan. A meta-analysis reported management changes in 54% (628/1,163) of its patients.40 An increase was seen in RT, surgery and multimodal treatment, with a decrease in systemic treatment referred as management change due to the ⁶⁸Ga-PSMA PET/CT scan findings. Calais et al.41 showed that, when changes based only on scans with positive findings were considered, 114 of 152 patients (75%) had management changes. The changes in management due to the impact of ⁶⁸Ga-PSMA PET/CT findings were measured as the fraction of patients who had a change in treatment plan after the scan. However, the intended management changes early after ⁶⁸Ga-PSMA PET/CT is usually different from implemented management changes. Post ⁶⁸Ga-PSMA PET, the number of systemic treatments decreased with increased local treatments.

High detection rate (74%) of ⁶⁸Ga-PSMA-11 PET, which was nearly 50% even in the patients with low PSA values, formed the basis for the changes in patient management. These detection rates were observed to be consistent, even in larger retrospective studies.42 Androgen deprivation treatment alters both PSMA status and PSMA PET. In a study by Müller et al.39 15.6% (33/223) of patients received androgen deprivation treatment at some point prior to the scan, with rise in PSA levels. Higher detection rate was observed in this subgroup compared to other groups (88% vs. 74%), with a positive scan in 31/35 patients. The high detection rate of recurrent PCA with ⁶⁸Ga-PSMA PET changed management in 60% of the patients. The patients were suggested to undergo salvage surgery, chemotherapy, radical therapy, or secondary hormonal therapy as management changes after the ⁶⁸Ga-PSMA-PET/CT scan.42 Moreover, this cohort (60%) showed a slightly high impact on management when compared to the management changes found by Afaq et al.43 (39% of patients) and Sterzing et al.44 (51% of patients).

The accuracy of ⁶⁸Ga-PSMA PET/CT scan has paved its way for future personalized treatment of PCa, as it has already replaced the conventional scans, like CT. This precise scanning may also aid in the development of various drugs to increase the precision or localization of the metastases.

### Hypothesis

The changes in management due to ⁶⁸Ga-PSMA PET/CT (Table 1) not only showed a clinical benefit in PCa patients with very low PSA values and BCR but also a benefit to the PCa patients with a higher risk even after the planned curative treatment. The sensitivity and specificity of this imaging technique decreased the possibility of unsatisfactory post-operative outcomes, while increasing the survival rate with better outcomes compared to the conventional treatments planned before the scan. ⁶⁸Ga-PSMA PET/CT could be advised in the routine check-up of PCa patients due to its effectiveness in the identification of metastasis followed by increased PSA levels, which are usually seen after the primary treatment. Another advantage of this type of scanning is that it can stage and image only the tumors and not any lesions. This precise scanning may also aid in the development of various drugs to increase the precision or localization of the metastases.

### Conclusions

⁶⁸Ga-PSMA PET/CT is effective in identifying recurrence localization and hence permits choosing the best therapeutic strategy as early as possible. ⁶⁸Ga-PSMA PET/CT shows a significant impact on the management changes in PCa patients.

### Acknowledgments

The authors thank Sri Ch. Venugopal Reddy, Chairman, Bharat Institutions, for his timely support in the accomplishment of this paper.

### Funding

Our study has not received any funding or grants, or any financial support.

---

**Table 1. Change of intended treatment options after ⁶⁸Ga-PSMA PET/CT imaging**

| Category                        | Treatment options                                      |
|---------------------------------|--------------------------------------------------------|
| Primary treatment               | Salvage surgery                                        |
|                                 | Salvage radiotherapy                                   |
|                                 | Metastasis-directed ablative radiation therapy (stereotactic body radiation therapy) |
|                                 | Androgen deprivation therapy                            |
|                                 | Chemotherapy                                            |
|                                 | PSMA radionuclide therapy                               |
|                                 | Other systemic treatment (vaccine therapy, immunotherapy) |
|                                 | Active surveillance                                     |
| Management changes chosen post-| Conversion to focal treatment                           |
| ⁶⁸Ga PSMA PET/CT imaging        | Conversion to new focal treatment                       |
|                                 | Conversion to systemic treatment                        |
|                                 | Changed systemic treatment (addition or removal of systemic treatment) |
|                                 | Conversion to active surveillance                       |

CT, computed tomography; PET, positron emission tomography; PSMA, prostate-specific membrane antigen.
Conflict of interest

The authors declare no conflict of interests.

Author contributions

Design, analysis and critical revisions of the manuscript (SG); design, coordination and drafting of the manuscript (SS, SK). All authors read and approved the final manuscript.

References

[1] Cancer Research UK. Prostate cancer statistics. 2017. Available from: https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/prostate-cancer. Accessed April 20, 2020.

[2] Cancer Australia. Prostate cancer in Australia. 2017. Available from: http://edcan.org.au/edcan-learning-resources/case-based-learning-resources/prostate-cancer/reduce-risk/australian-context. Accessed April 20, 2020.

[3] Dong L, Zieren RC, Xue W, de Reijke TM, Pienta KJ. Metastatic prostate cancer after local therapy: evolving standards of care and diagnostic resonance imaging? Pol J Radiol 2019;84:e46–e53. doi:10.5114/pjr.2019.84.2.82736.

[4] Paller CJ, Antonarakis ES. Management of biochemically recurrent prostate cancer after local therapy: evolving standards of care and new directions. Clin Adv Hematol Oncol 2013;11(1):14–23.

[5] Yuminaga Y, Rothe C, Kam J, Beattie K, Arianayagam M, Bui C, et al. 68Ga-PSMA-PET/CT versus CT and bone scan for investigation of PSA failure post radical prostatectomy. Asian J Urol 2020. doi:10.1016/j.ajur.2020.02.001.

[6] Cancer.Net Editorial Board. Breast Cancer: Types of Treatment. 2019. Available from: https://www.cancer.net/cancer-types/breast-cancer/types-treatment. Accessed April 20, 2020.

[7] Hofman M. PSMA PET/CT for staging and treatment of prostate cancer. Eur J Nucl Med Mol Imaging 2018;45(12):1941–1944. doi:10.1007/s00259-018-3733-4.

[8] Barbosa FG, Queiroz MA, Nunes RF, Marin JFG, Buchpiguel CA, Cerri F, et al. 68Ga-PSMA-PET/CT imaging. Nucl Med Commun 2016;37(11):1169–1179. doi:10.1093/nucmed/nov085.

[9] Eiber M, Maurer T, Souvatzoglou M, Beer AJ, Haller B, Eder M, et al. Evaluation of hybrid Ga-PSMA ligand HDR-EC for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesion. Eur J Nucl Med Mol Imaging 2013;40(4):486–495. doi:10.1007/s00259-012-2294-z.

[10] Afschar-Oromieh A, Malcher A, Eder M, Eisenhut M, Linhart HG, Hadaschik BA, et al. PET imaging with a [68Ga]labeled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesion. Eur J Nucl Med Mol Imaging 2013;40(4):486–495. doi:10.1007/s00259-012-2294-z.

[11] Yang MP, Ballal S, Saooh RK, Dwivedi SN, Bal C. Radioligand Therapy With 177Lu-PSMA for Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis. J Urol Am J Roentgenol 2019;213(2):275–285. doi:10.2214/AJR.18.20845.

[12] Fendler WP, Rahbar K, Honemann K, Kratochwil C, Eiber M. 177Lu-PSMA Radioligand Therapy for Prostate Cancer. J Nucl Med 2017;58(8):1196–1200. doi:10.2967/jnumed.117.191023.

[13] Boegemann M, Schrader AJ, Rahbar K. 177Lu-PSMA therapy: current evidence for use in the treatment of patients with metastatic prostate cancer (in German). Urologe A 2017;56(11):1440–1444. doi:10.1007/s00120-017-0510-5.

[14] Calopedos RJS, Chalasani V, Asher R, Emmett L, Woo HH. Lutetium-177-labelled anti-prostate-specific membrane antigen antibody and ligands for the treatment of metastatic castrate-resistant prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis 2017;20(3):352–360. doi:10.1038/jpcrd.2017.23.

[15] Emmett L, Willowsen K, Violet J, Shin J, Blanksby A, Lee J. Lutetium 177 PSMA radionuclide therapy for men with prostate cancer: A review of the current literature and discussion of practical aspects of therapy. J Med Radiat Sci 2017;64(1):52–60. doi:10.1007/j.12536.2017.01227.

[16] Werner RA, Chen X, Rowe SP, Lapa C, Javadi MS, Hiughton TM. Moving Into the Next Era of PET Myocardial Perfusion Imaging: Introduction of Novel 18F-Labelled Tracers. Int J Cardiovasc Imaging 2019;35(3):569–577. doi:10.1007/s10554-018-1469-z.

[17] Boegemann M, Schrader AJ, Rahbar K. 177Lu-PSMA therapy dosimetry and follow-up in patients with metastatic castration-resistant prostate cancer (in German). Nuklearmedizin 2016;55(3):123–128.

[18] Ranasinghe C, Cholletille M, Simecek J, Baum RP, Yildiz A, Beykan S, et al. Lutetium 177 Ga and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies. J Nucl Med 2015;56(8):1169–1176. doi:10.2967/jnumed.115.158550.

[19] Kesavam, Turner JH, Meyrick D, Yeo S, Cardaci G, Lenzo NP. Salvage Radiopeptide Therapy of Advanced Castrate Resistant Prostate Cancer with Lutetium-177 labelled Prostate Specific Membrane Antigen (177Lu-PSMA): Efficacy and safety in Routine Practice. Cancer Biother Radiopharm 2018;33(7):274–281. doi:10.1089/cbr.2017.2403.

[20] Lenzo NP, Meyrick D, Turner JH. Review of Gallium-68 PSMA PET/CT Imaging in the Management of Prostate Cancer. Diagnostics (Basel) 2018;8(1):16. doi:10.3390/diagnostics8010016.

[21] Fanti S, Sanz G, Robles JE, Gimenez M, Arocena J, Sanchez D, Rodriguez-Ruiz M, et al. F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. Eur J Nucl Med Mol Imaging 2017;44(4):678–688. doi:10.1007/s00259-016-3573-4.

[22] Fendler WP, Rahbar K, Hermsmeyer K, Kratochwil C, Eiber M. 177Lu-PSMA Therapy for Metastatic Castration-Resistant Prostate Cancer. J Nucl Med 2019;213(2):275–285. doi:10.2214/AJR.18.20845.

[23] Afshar-Oromieh A, Avtzi E, Giesel FL, Holland-Letz T, Linhart HG, Eiber M, et al. The diagnostic value of PET/CT imaging with the 68Ga labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 2015;42(2):197–209. doi:10.1007/s00259-014-2949-y.

[24] Eiber M, Maurer T, Souvatzoglou M, Beer AJ, Ruffani A, Haller B, et al. Evaluation of hybrid 68Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med 2015;56(5):668–674. doi:10.2967/jnumed.115.141513.

[25] Morris MJ, Akhurst T, Osman I, Nunez R, Macapinlac H, Siedlecki K, et al. Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer. Urology 2002;59(6):913–918. doi:10.1016/S0090-4295(02)01509-1.

[26] Sanz G, Robles JE, Gimenez M, Arocena J, Sanchez D, Rodriguez-Ru-
bio F, et al. Positron emission tomography with 18fluorine-labelled deoxyglucose: utility in localized and advanced prostate cancer. BJU Int 1999;84:1028–1031. doi:10.1046/j.1464-410x.1999.00349.x.

[33] Minamimoto R, Uemura H, Sano F, Terao H, Nagashima Y, Yamanaka S, et al. The potential of FDG-PET/CT for detecting prostate cancer in patients with an elevated serum PSA level. Ann Nucl Med 2011;25(1):21–27. doi:10.1007/s12149-010-0424-4.

[34] Shiiba M, Ishihara K, Kimura G, Kuwako T, Yoshihara H, Sato H, et al. Evaluation of primary prostate cancer using 11C-methionine-PET/CT and 18F-FDG-PET/CT. Ann Nucl Med 2012;26(2):138–145. doi:10.1007/s12149-011-0551-6.

[35] Effert P, Beniers AJ, Tamimi Y, Handt S, Jakse G. Expression of glucose transporter 1 (Glut-1) in cell lines and clinical specimens from human prostate adenocarcinoma. Anticancer Res 2004;24(5A):3057–3063.

[36] Soyka JD, Muster MA, Schmid DT, Seifert B, Schick U, Miralbell R, et al. Clinical impact of 18F-choline PET/CT in patients with recurrent prostate cancer. Eur J Nucl Med Mol Imaging 2012;39(6):936–943. doi:10.1007/s00259-012-2083-2.

[37] Roach PJ, Francis R, Emmett L, Hsiao E, Kneebone A, Hruby G, et al. The impact of 68Ga-PSMA PET/CT on management intent in prostate cancer: results of an Australian prospective multicenter study. J Nucl Med 2018;59(1):82–88. doi:10.2967/jnumed.117.197160.

[38] Bluemel C, Linke F, Herrmann K, Simunovic I, Eber M, Kestler C, et al. Impact of 68Ga-PSMA PET/CT on salvage radiotherapy planning in patients with prostate cancer and persisting PSA values or biochemical relapse after prostatectomy. EJNMMI Res 2016;6(1):78. doi:10.1186/s13550-016-0233-4.

[39] Müller J, Ferraro DA, Muehlmatten UJ, Schüler HIG, Kedzia S, Eberli D, et al. Clinical impact of 68Ga-PSMA-11 PET on patient management and outcome, including all patients referred for an increase in PSA level during the first year after its clinical introduction. Eur J Nucl Med Mol Imaging 2019;46(4):889–900. doi:10.1007/s00259-018-4203-0.

[40] Han S, Woo S, Kim YJ, Suh CH. Impact of 68Ga-PSMA PET on the management of patients with prostate cancer: a systematic review and meta-analysis. Eur Urol 2018;74(2):179–190. doi:10.1016/j.eururo.2018.03.030.

[41] Calais J, Fendler WP, Eiber M, Gartmann J, Chu F, Nichols NG, et al. Impact of 68Ga-PSMA-11 PET/CT on the management of prostate cancer patients with biochemical recurrence. J Nucl Med 2018;59(3):434–441. doi:10.2967/jnumed.117.202945.

[42] Mattioli AB, Santos A, Vicente A, Queiroz M, Bastos D, Herchenhorn D, et al. Impact of 68Ga-PSMA-PET/CT on treatment of patients with recurrent/metastatic high risk prostate cancer - a multicenter study. Int Braz J Urol 2018;44(5):892–899. doi:10.1590/S1677-5538.IBU.2017.0632.

[43] Afaq A, Alahmed S, Chen SH, Lengana T, Haroon A, Payne H, et al. Impact of 68Ga-prostate-specific membrane antigen PET/CT on prostate cancer management. J Nucl Med 2018;59(1):89–92. doi:10.2967/jnumed.117.192625.

[44] Sterzing F, Kratochwil C, Fiedler H, Katayama S, Habi G, Kopka K, et al. (68)Ga-PSMA-11 PET/CT: a new technique with high potential for the radiotherapeutic management of prostate cancer patients. Eur J Nucl Med Mol Imaging 2016;43(1):34–41. doi:10.1007/s00259-015-3188-1.